WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, May 09, 2005

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND	
☐	L1	dam same (dna or cdna or antisense or gene or operon or coding or encoding or nucleotide or nucleic or nuclear or polynucleotide or poly-nucleotide or rna or mrna)	1960
☐	L2	dam.clm. same (dna or cdna or antisense or gene or operon or coding or encoding or nucleotide or nucleic or nuclear or polynucleotide or poly-nucleotide or rna or mrna).clm.	73
☐	L3	L2 and (method or process).clm.	54
☐	L4	mahan.in.	648
☐	L5	L4 and salmonell$	19
☐	L6	l5 and (methylase or methyl-ase or methyltransferase or methyl-transferase or dam or dam-methylase or dammethylase)	13

END OF SEARCH HISTORY

. 20050079618. 07 May 04. 14 Apr 05. Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids. Court, Donald L., et al. 435/471; 435/488 C12N015/74.

☐ 2. 20050035484. 12 Aug 03. 17 Feb 05. Recyclable composite materials articles of manufacture and structures and method of using composite materials. Meyers III, John J., et al. 264/162; 106/287.35 156/94 264/320 264/322 264/349 524/439 524/442 524/68 C08K003/08 C08K003/40 C08K005/01.

☐ 3. 20040265337. 21 Aug 03. 30 Dec 04. Method of generating an immune response and compositions used for same. Zsebo, Krisztina M., et al. 424/200.1; A61K039/02.

☐ 4. 20040214197. 17 Nov 03. 28 Oct 04. Method of preparing polynucleotide fragments for use in shuffling, and shuffling of same. Dupret, Daniel, et al. 435/6; 435/455 435/91.2 C12Q001/68 C12P019/34 C12N015/85.

☐ 5. 20040192631. 24 Mar 04. 30 Sep 04. DNA vaccines against tumor growth and methods of use thereof. Xiang, Rong, et al. 514/44; A61K048/00.

☐ 6. 20040120962. 15 Apr 03. 24 Jun 04. Modulation of immune responses to foreign antigens expressed by recombinant attenuated bacterial vectors. Curtiss, Roy III, et al. 424/184.1; A61K039/00 A61K039/38.

☐ 7. 20040101531. 15 Apr 03. 27 May 04. Immunogenic compositions and vaccines comprising carrier bacteria that secrete antigens. Curtiss, Roy III, et al. 424/184.1; A61K039/00 A61K039/38.

☐ 8. 20040096864. 16 Dec 03. 20 May 04. Method of eukaryotic expression cloning of disease associated molecules. Carroll, Miles W., et al. 435/6; 435/456 C12Q001/68 C12N015/86.

☐ 9. 20040057958. 19 May 03. 25 Mar 04. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same. Waggoner, David W. JR., et al. 424/184.1; 514/54 530/403 A61K039/00 C07K014/00.

☐ 10. 20040029183. 08 Jul 02. 12 Feb 04. Apparatus and method for detecting and classifying chemicals, particles, vira, and bacteria in fluids. Liebholz, Stephen W., et al. 435/7.2; G01N033/53.

☐ 11. 20040014083. 24 Feb 03. 22 Jan 04. Detection of heteroduplex polynucleotides using mutant nucleic acid repair enzymes with attenuated catalytic activity. Yuan, Chong-Sheng, et al. 435/6; C12Q001/68.

☐ 12. 20040009939. 03 Mar 03. 15 Jan 04. Methods of enhancing immune induction involving MDA-7. Chada, Sunil, et al. 514/44; 424/93.2 514/12 A61K048/00 A61K038/17.

☐ 13. 20030203425. 25 Mar 03. 30 Oct 03. Hybrid glycosylated products and their production and use. Leadlay, Peter Francis, et al. 435/68.1; 435/101 435/193 435/75 C12P021/06 C12P019/60 C12P019/04 C12N009/10.

☐ 14. 20030129603. 24 Oct 01. 10 Jul 03. Databases of regulatory sequences; methods of making and using same. Wolffe, Alan P., et al. 435/6; 435/270 536/25.4 C12Q001/68 C07H021/04.

☐ 15. 20030124725. 06 Sep 00. 03 Jul 03. Mutagenesis method. Tanabe, Kiyoshi, et al. 435/455; 435/471 435/91.2 C12P019/34 C12N015/74 C12N015/85.

☐ 16. 20030031683. 03 May 02. 13 Feb 03. Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS positive phenotype. Curtiss, Roy III, et al. 424/200.1; 424/258.1 424/93.2 435/252.3 435/252.8 435/471 435/897 A61K048/00 A01N063/00 A61K039/02 C12N001/20 A61K039/112 C12N015/74 C12N001/00.

☐ 17. 20030003472. 20 Feb 02. 02 Jan 03. Mismatch repair detection. Cox, David R., et al. 435/6; 435/471 435/484 435/488 C12Q001/68 C12N015/74.

☐ 18. 20020086332. 09 Aug 01. 04 Jul 02. Method of reducing bacterial proliferation. Mahan, Michael J., et al. 435/7.1; G01N033/53.

☐ 19. 20020086032. 09 Aug 01. 04 Jul 02. Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity. Mahan, Michael J., et al. 424/200.1; 435/252.3 A61K039/02 C12N001/21.

☐ 20. 20020081603. 27 Apr 01. 27 Jun 02. Databases of regulatory sequences; methods of making and using same. Wolffe, Alan, et al. 435/6; 435/91.2 C12Q001/68 C12P019/34.

☐ 21. 20020077272. 09 Aug 01. 20 Jun 02. Reducing bacterial virulence. Mahan, Michael J., et al. 514/1; 514/263.4 A61K031/00 A61K031/52.

☐ 22. 20020076417. 09 Aug 01. 20 Jun 02. Attenuated bacteria with altered DNA adenine methylase activity. Mahan, Michael J., et al. 424/200.1; 435/252.3 435/252.33 435/252.35 A61K039/02 C12N001/21.

☐ 23. 20020068068. 09 Aug 01. 06 Jun 02. Method of creating antibodies and compositions used for same. Mahan, Michael J., et al. 424/200.1; 424/257.1 424/258.1 424/261.1 A61K039/108 A61K039/112 A61K039/106 A61K039/02.

☐ 24. 6501413. 22 Mar 99; 31 Dec 02. Timing and control and data acquisition for a multi transducer ground penetrating radar system. Annan; Alexander Peter, et al. 342/22; 342/190. G01V003/12.

☐ 25. 6463180. 10 May 00; 08 Oct 02. Spatial index compression through spatial subdivision encoding. Krishnaswamy; Ravinder Patnam. 382/240;. G06K009/36.

☐ 26. 6399856. 19 Nov 98; 04 Jun 02. Reversible nuclear genetic system for male sterility in transgenic plants. Cigan; Andrew M., et al. 800/274; 536/24.1 800/275 800/278. A01H001/00 A01H001/022 A01H015/82.

☐ 27. 6383496. 18 May 99; 07 May 02. Recombinant vaccines comprising immunogenic attenuated bacteria having RPOS positive phenotype. Curtiss, III; Roy, et al. 424/200.1; 424/258.1 424/93.2 435/252.3 435/252.8 435/471 435/897. A61K039/02 A61K048/00 C12N015/74 C12N001/21.

☐ 28. 6300084. 06 Oct 99; 09 Oct 01. Anti-mitotic agent screening process. Drubin; David G., et al. 435/7.1; 424/277.1 424/93.21 435/320.1 435/325 435/477 514/44 530/350 536/23.1. G01N033/53 C07K001/00 C07K014/00 C07K017/00 C07H021/02.

☐ 29. 6287825. 17 Sep 99; 11 Sep 01. Methods for reducing the complexity of DNA sequences. Weissman; Sherman, et al. 435/91.2; 435/6 435/91.1 436/94 536/23.1 536/24.3 536/24.33. C12P019/34 C12Q001/68 G01N033/00 C07H021/02 C07H021/04.

☐ 30. 6248935. 28 Nov 97; 19 Jun 01. Reversible nuclear genetic system for male sterility in transgenic plants. Cigan; Andrew M., et al. 800/267; 536/23.6 536/23.7 536/24.1 800/266 800/271 800/274. C12N001/00 A01H005/00 A01H005/04.

☐ 31. 6150112. 17 Sep 99; 21 Nov 00. Methods for identifying DNA sequences for use in comparison of DNA samples by their lack of polymorphism using Y shape adaptors. Weissman; Sherman, et al. 435/6; 435/91.1 435/91.2 536/23.1 536/24.2. C12Q001/68 C07H021/02.

☐ 32. 6144336. 13 May 99; 07 Nov 00. System and method to communicate time stamped, 3-axis geo-position data within telecommunication networks. Preston; Dan A., et al. 342/357.09; 455/456.5. H04B007/26.

☐ 33. 6132318. 02 Mar 98; 17 Oct 00. Interactive funhouse play structure. Briggs; Rick A.. 472/128;. A63G031/00.

☐ 34. 6072102. 28 Nov 97; 06 Jun 00. Reversible nuclear genetic system for male sterility in transgenic plants. Cigan; Andrew M., et al. 800/274; 536/24.1 800/271 800/275 800/285 800/288. A01H001/00 C12M015/00.

☐ 35. 6037523. 23 Jun 97; 14 Mar 00. Male tissue-preferred regulatory region and method of using same. Albertsen; Marc C., et al. 800/287; 435/419 536/23.6 536/24.1 800/268 800/271 800/274 800/298 800/303. C12N015/00 C12N005/00 A01H001/06 A01H004/00.

☐ 36. 6004750. 04 Aug 97; 21 Dec 99. Nucleic acid clamps. Frank-Kamenetskii; Maxim D., et al. 435/6; 435/183 435/69.1 435/91.1 536/23.1 536/24.31 536/24.32. C12Q001/68 C12P021/00 C12N009/00 C07H021/04.

☐ 37. 5792853. 07 Jun 95; 11 Aug 98. Reversible nuclear genetic system for male sterility in transgenic plants. Cigan; Andrew M., et al. 536/24.1; 47/DIG.1 536/23.1 536/23.6 800/303. C07H021/02 C07H021/04 C12N015/00 C12N015/05.

☐ 38. 5773697. 23 Apr 96; 30 Jun 98. Genetic constructs and methods for producing fruits with very little or diminished seed. Tomes; Dwight T., et al. 800/260; 435/320.1 435/69.1 536/23.7 536/24.1 800/268 800/287 800/290 800/298 800/308 800/309. C12N015/29 C12N015/82 A01H004/00 A01H005/00.

☐ 39. 5750868. 08 Dec 94; 12 May 98. Reversible nuclear genetic system for male sterility in transgenic plants. Cigan; Andrew M., et al. 800/274; 435/424 435/430 47/DIG.1 536/24.1 536/27.1 800/287 800/303. C12H015/00 C12H015/05 A01H001/06 A01H004/00.

☐ 40. 5745696. 10 Apr 95; 28 Apr 98. Transport controller for timed program data. Mendelson; Jeffrey B., et al. 709/233; 370/468 709/231 709/236. H04J014/08 H04J003/22.

☐ 41. 5721746. 19 Apr 96; 24 Feb 98. Optimal soft-output decoder for tail-biting trellis codes. Hladik; Stephen Michael, et al. 714/792;. H03M013/12.

☐ 42. 5719784. 07 Jun 95; 17 Feb 98. Order-based analyses of cell and tissue structure. Clark; John I., et al. 702/28; 382/133 702/77. G01N033/48 G01N033/483 G06F017/159.

☐ 43. 5717641. 30 Jul 96; 10 Feb 98. Method of storing data and a data storing apparatus. Ando;

Ichiro, et al. 365/191; 365/198 365/233 365/239 370/503 370/505. H04B014/04 H04N007/137.

☐ 44. 5717129. 16 Feb 95; 10 Feb 98. Methods for maintaining sterility in plants. Songstad; David D., et al. 800/266; 47/DIG.1 800/274 800/298 800/300 800/300.1 800/303 800/320.1. A01H001/06 A01H004/00 C12N015/00 C12N015/63.

☐ 45. 5689049. 07 Jun 95; 18 Nov 97. Transgenic plant and method for producing male sterility using anther specific promoter 5126. Cigan; Andrew M., et al. 800/287; 47/DIG.1 536/24.1 800/303. C12N015/00 C12N015/05 A01H001/06 A01H004/00.

☐ 46. 5432821. 02 Dec 92; 11 Jul 95. System and method for estimating data sequences in digital transmissions. Polydoros; Andreas, et al. 375/340; 375/349. H03D001/00 H04L027/06.

☐ 47. 5386234. 05 Nov 92; 31 Jan 95. Interframe motion predicting method and picture signal coding/decoding apparatus. Veltman; Markus H., et al. 375/240.13;. H04N007/133 H04N007/137.

☐ 48. 5383219. 22 Nov 93; 17 Jan 95. Fast forward link power control in a code division multiple access system. Wheatley, III; Charles E., et al. 370/342; 370/209 375/130 380/34 714/786. H04K001/00.

☐ 49. 5351274. 20 Aug 93; 27 Sep 94. Post detection selection combining diversity receivers for mobile and indoor radio channels. Chennakeshu; Sandeep, et al. 375/347; 375/341 455/135 455/137. H04L001/06 H04B007/04.

☐ 50. 5331674. 31 Dec 92; 19 Jul 94. Nuclear reactor coolant system inventory control system and method. Evans; Cliff, et al. 376/204; 376/260. G21C013/00.

Generate Collection Print

Terms	Documents
L2 and (method or process).clm.	54

Prev Page Next Page

1. 20040126871. 24 Nov 03. 01 Jul 04. Nucleic acid vaccines against rickettsial diseases and methods of use. Barbet, Anthony F., et al. 435/252.3; C12N001/20.

2. 20020132789. 31 Jan 02. 19 Sep 02. Nucleic acid vaccines against rickettsial diseases and methods of use. Barbet, Anthony F., et al. 514/44; 536/23.7 A61K048/00 C07H021/04.

3. 20020086332. 09 Aug 01. 04 Jul 02. Method of reducing bacterial proliferation. Mahan, Michael J., et al. 435/7.1; G01N033/53.

4. 20020086032. 09 Aug 01. 04 Jul 02. Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity. Mahan, Michael J., et al. 424/200.1; 435/252.3 A61K039/02 C12N001/21.

5. 20020081317. 09 Aug 01. 27 Jun 02. Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope. Mahan, Michael J., et al. 424/200.1; 435/252.3 435/320.1 A61K039/02 C12N001/21 C12N015/74.

6. 20020077272. 09 Aug 01. 20 Jun 02. Reducing bacterial virulence. Mahan, Michael J., et al. 514/1; 514/263.4 A61K031/00 A61K031/52.

7. 20020076417. 09 Aug 01. 20 Jun 02. Attenuated bacteria with altered DNA adenine methylase activity. Mahan, Michael J., et al. 424/200.1; 435/252.3 435/252.33 435/252.35 A61K039/02 C12N001/21.

8. 20020068068. 09 Aug 01. 06 Jun 02. Method of creating antibodies and compositions used for same. Mahan, Michael J., et al. 424/200.1; 424/257.1 424/258.1 424/261.1 A61K039/108 A61K039/112 A61K039/106 A61K039/02.

9. 6653128. 31 Jan 02; 25 Nov 03. Nucleic acid vaccines against rickettsial diseases and methods of use. Barbet; Anthony F., et al. 435/320.1; 514/44 530/350 536/23.7. C07H021/04 C12N015/00 A01N043/04 A61K031/70.

10. 6593147. 21 Apr 00; 15 Jul 03. Nucleic acid vaccines against rickettsial diseases and methods of use. Barbet; Anthony F., et al. 436/518; 435/7.1 436/501. G01N033/543.

11. 6548246. 17 Nov 98; 15 Apr 03. Method and probes for the identification of microbial genes specifically induced during host infection. Mahan; Michael J., et al. 435/6; 435/471 435/477 435/479 435/480. C12Q001/68.

12. 6365401. 17 May 96; 02 Apr 02. Method and probes for the identification of microbial genes specifically induced during host infection. Mahan; Michael J., et al. 435/320.1; 536/23.1 536/23.7. C12N019/31.

13. 5434065. 06 May 93; 18 Jul 95. In vivo selection of microbial virulence genes. Mahan; Michael J., et al. 435/6; 435/243 435/252.3 435/477 435/480 435/91.1 435/91.41. C12N015/09 C12N015/10.

14. US20020086032A. Attenuated strain of bacteria useful for eliciting immune response in an individual, has altered DNA adenine methylase activity. HEITHOFF, D M, et al. A61K039/02 C12N001/21.

☐ 15. US20020081317A. Immunogenic composition, useful to prevent or treat pathogenic bacterial infection, comprises live bacteria with DNA adenine methylase activity altered relative to wild-type, and which also express a heterologous antigen. HEITHOFF, D M, et al. A61K039/02 C12N001/21 C12N015/74.

☐ 16. US20020076417A. New strain of attenuated bacterium, useful in vaccines, has alteration in activity of DNA adenine methylase, induces higher levels of immunoglobulins. HEITHOFF, D M, et al. A61K039/02 C12N001/21.

☐ 17. US20020077272A. Reducing bacterial virulence using an agent that alters the bacteria's native level of DNA methyltransferase activity. HEITHOFF, D M, et al. A61K031/00 A61K031/52.

☐ 18. WO 200045840A. New vaccine compositions comprising pathogenic bacteria which contain a mutation affecting DNA adenine methylase, useful for treating or preventing bacterial infection, especially Salmonella infection, in humans and domestic animals. HEITHOFF, D M, et al. A61K000/00 A61K039/00 A61K039/02 A61K039/095 A61K039/10 A61K039/102 A61K039/106 A61K039/108 A61K039/112 A61K048/00 A61P031/04 A61P037/00 C12N001/20 C12N001/21 C12N001/36 C12N001:20 C12N015/74 C12R001/42 C12R001:42 G01N033/02 G01N033/15 G01N033/50 G01N033/53 G01N033/566 C12N001/20 C12R001:42.

☐ 19. US 5434065A. Selecting microbial genes specifically induced during infection - using suicide vector for integrating chromosomal fragments into a microorganism and isolating strains that can grow in a host.. MAHAN, M J, et al. C12N015/09 C12N015/10.

Generate Collection Print

Terms	Documents
L4 and salmonell$	19

Prev Page Next Page Go to Do

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L3: Entry 15 of 54 File: PGPB Jul 3, 2003

DOCUMENT-IDENTIFIER: US 20030124725 A1
TITLE: Mutagenesis method

CLAIMS:

1. A method for mutagenesis of a gene, which comprises introducing much more point mutations into one strand of double-stranded genomic DNA of cell or organism individual than into another strand.

2. The method according to claim 1, wherein the point mutations are randomly introduced into four kinds of bases.

3. The method according to claim 1 or 2, wherein the cell or the organism individual is mutant cell strain or mutant organism individual having mutator gene in a mutation repair gene group.

4. The method mutation according to claim 3, wherein the mutator gene is one or more mutator genes selected from a group consisting of dnaQ, dnaE, mutL, mutS, mutH, uvrD and dam.

5. The method according to claim 3 or 4, wherein the mutator gene is a gene which causes a defect of mutation repair mechanism under a certain condition.

6. The method according to claim 5, wherein the condition for the defect of the mutation repair mechanism is a certain temperature.

7. The method according to claim 5 or 6, wherein a step of introduction of mutation into genomic DNA under a certain condition and a step of selection of mutant under a selection load condition without introduction of mutation are repeated.

8. The method according to claim 7, wherein the step of introduction of mutation at the second time and thereafter are carried out under the same selection load as that in the step of mutant selection immediately therebefore.

9. A mutant of cell or organism individual where mutation is introduced into genomic DNA by any of the methods of claims 1 to 8.

Previous Doc Next Doc Go to Doc#

L3: Entry 19 of 54 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086032
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086032 A1

TITLE: Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mahan, Michael J.	Santa Barbara	CA	US	
Heithoff, Douglas M.	Goleta	CA	US	
Low, David A.	Goleta	CA	US	
Sinsheimer, Robert L.	Santa Barbara	CA	US	

APPL-NO: 09/ 927896 [PALM]
DATE FILED: August 9, 2001

RELATED-US-APPL-DATA:
Application 09/927896 is a continuation-in-part-of US application 09/612116, filed July 7, 2000, PENDING
Application 09/612116 is a continuation-in-part-of US application 09/495614, filed February 1, 2000, PENDING
Application is a non-provisional-of-provisional application 60/183043, filed February 2, 1999,
Application is a non-provisional-of-provisional application 60/198250, filed May 5, 1999,

INT-CL: [07] A61 K 39/02, C12 N 1/21

US-CL-PUBLISHED: 424/200.1; 435/252.3
US-CL-CURRENT: 424/200.1; 435/252.3

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention is directed towards methods of producing antibodies using an attenuated strain of pathogenic bacteria (e.g. Haemophilus, E. coli, and/or Salmonella) having non-reverting genetic mutations relative to the wild-type organism which alter activity of DNA adenine methylase (Dam). The invention further includes compositions comprised of the attenuated bacteria and methods using these compositions to elicit an immune response and immunize a subject with highly specific antibodies. The invention also provides methods producing antibodies to heterologous antigens which the attenuated bacteria are engineered to produce.

CROSS-REFERENCE

[0001] This patent application is a continuation-in-part of U.S. patent application Ser. No. 09/612,116 filed Jul. 7, 2000 which is a continuation-in-part of U.S. patent application Ser. No. 09/495,614, filed Feb. 1, 2000, which claims the priority benefit of U.S. patent application Ser. Nos. 09/241,951, filed Feb. 2, 1999, converted to U.S. Provisional Ser. No. 60/183,043, and 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. 60/198,250, all of which are incorporated by reference in their entirety and to which applications is claimed priority.

Previous Doc Next Doc Go to Doc#

L3: Entry 18 of 54 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086332
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086332 A1

TITLE: Method of reducing bacterial proliferation

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mahan, Michael J.	Santa Barbara	CA	US	
Heithoff, Douglas M.	Goleta	CA	US	
Low, David A.	Goleta	CA	US	
Sinsheimer, Robert L.	Santa Barbara	CA	US	

APPL-NO: 09/ 928227 [PALM]
DATE FILED: August 9, 2001

RELATED-US-APPL-DATA:
Application 09/928227 is a continuation-in-part-of US application 09/612116, filed July 7, 2000, PENDING
Application 09/612116 is a continuation-in-part-of US application 09/495614, filed February 1, 2000, PENDING
Application is a non-provisional-of-provisional application 60/183043, filed February 2, 1999,
Application is a non-provisional-of-provisional application 60/198250, filed May 5, 1999,

INT-CL: [07] G01 N 33/53

US-CL-PUBLISHED: 435/7.1
US-CL-CURRENT: 435/7.1

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

Bacteria and in particular pathogenic bacteria are treated in a manner which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The alteration results in a change in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds which inhibit proliferation of bacteria are useful in treating bacterial infections.

CROSS-REFERENCE

[0001] This patent application is a continuation-in-part of U.S. patent application Ser. No. 09/612,116 filed Jul. 7, 2000 which is a continuation-in-part of U.S. patent application Ser. No. 09/495,614, filed Feb. 1, 2000, which claims the priority benefit of U.S. patent application Ser. Nos. 09/241,951, filed Feb. 2, 1999, converted to U.S. Provisional Ser. No. 60/183,043, and 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. 60/198,250, all of which are incorporated by reference in their entirety and to which applications is claimed priority.

Previous Doc Next Doc Go to Doc#

L3: Entry 21 of 54 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020077272
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020077272 A1

TITLE: Reducing bacterial virulence

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mahan, Michael J.	Santa Barbara	CA	US	
Heithoff, Douglas M.	Goleta	CA	US	
Low, David A.	Goleta	CA	US	
Sinsheimer, Robert L.	Santa Barbra	CA	US	

APPL-NO: 09/ 927885 [PALM]
DATE FILED: August 9, 2001

RELATED-US-APPL-DATA:
Application 09/927885 is a continuation-in-part-of US application 09/612116, filed July 7, 2000, PENDING
Application 09/612116 is a continuation-in-part-of US application 09/495614, filed February 1, 2000, PENDING
Application is a non-provisional-of-provisional application 60/183043, filed February 2, 1999,
Application is a non-provisional-of-provisional application 60/198250, filed May 5, 1999,

INT-CL: [07] A61 K 31/00, A61 K 31/52

US-CL-PUBLISHED: 514/1; 514/263.4
US-CL-CURRENT: 514/1; 514/263.4

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The virulence of bacterial strains and in particular pathogenic bacteria which infect human is reduced by an agent which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The agent causes an alteration in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds and formulations thereof which reduce bacterial virulence inhibit proliferation of bacteria and are useful in treating bacterial infections, particularly in humans.

CROSS-REFERENCE

[0001] This patent application is a continuation-in-part of U.S. patent application Ser. No. 09/612,116 filed Jul. 7, 2000 which is a continuation-in-part of U.S. patent application Ser. No. 09/495,614, filed Feb. 1, 2000, which claims the priority benefit of U.S. patent application Ser. No. 09/241,951, filed Feb. 2, 1999, converted to U.S. Provisional Ser. No. 60/183,043, and Ser. No. 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. 60/198,250, all of which are incorporated by reference in their entirety and to which applications is claimed priority.

Previous Doc Next Doc Go to Doc#

L3: Entry 22 of 54 File: PGPB Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020076417 A1

TITLE: Attenuated bacteria with altered DNA adenine methylase activity

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mahan, Michael J.	Santa Barbara	CA	US	
Heithoff, Douglas M.	Goleta	CA	US	
Low, David A.	Goleta	CA	US	
Sinsheimer, Robert L.	Santa Barbara	CA	US	

APPL-NO: 09/ 927767 [PALM]
DATE FILED: August 9, 2001

RELATED-US-APPL-DATA:
Application 09/927767 is a continuation-in-part-of US application 09/612116, filed July 7, 2000, PENDING
Application 09/612116 is a continuation-in-part-of US application 09/495614, filed February 1, 2000, PENDING
Application is a non-provisional-of-provisional application 60/183043, filed February 2, 1999,
Application is a non-provisional-of-provisional application 60/198250, filed May 5, 1999,

INT-CL: [07] A61 K 39/02, C12 N 1/21

US-CL-PUBLISHED: 424/200.1; 435/252.3, 435/252.33, 435/252.35
US-CL-CURRENT: 424/200.1; 435/252.3, 435/252.33, 435/252.35

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention is directed towards an attenuated strain of pathogenic bacteria (e.g. Haemophilus, E. Coli, and/or Salmonella) having non-reverting genetic mutations relative to the wild-type organism which alter activity of DNA adenine methylase (Dam). The invention further includes compositions comprised of the attenuated bacteria and methods using these compositions to elicit an immune response to produce highly specific antibodies. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.

CROSS-REFERENCE

[0001] This patent application is a continuation-in-part of U.S. patent application Ser. No. 09/612,116 filed Jul. 7, 2000 which is a continuation-in-part of U.S. patent application Ser. No. 09/495,614, filed Feb. 1, 2000, which claims the priority benefit of U.S. patent application Ser. Nos. 09/241,951, filed Feb. 2, 1999, converted to U.S. Provisional Ser. No. 60/183,043, and 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. 60/198,250, all of which are incorporated by reference in their entirety and to which applications is claimed priority.

Previous Doc Next Doc Go to Doc#

L3: Entry 23 of 54 File: PGPB Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068068
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068068 A1

TITLE: Method of creating antibodies and compositions used for same

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mahan, Michael J.	Santa Barbara	CA	US	
Heithoff, Douglas M.	Goleta	CA	US	
Low, David A.	Goleta	CA	US	
Sinsheimer, Robert L.	Santa Barbara	CA	US	

APPL-NO: 09/ 927765 [PALM]
DATE FILED: August 9, 2001

RELATED-US-APPL-DATA:
Application 09/927765 is a continuation-in-part-of US application 09/612116, filed July 7, 2000, PENDING
Application 09/612116 is a continuation-in-part-of US application 09/495614, filed February 1, 2000, PENDING
Application is a non-provisional-of-provisional application 60/183043, filed February 2, 1999,
Application is a non-provisional-of-provisional application 60/198250, filed May 5, 1999,

INT-CL: [07] A61 K 39/108, A61 K 39/112, A61 K 39/106, A61 K 39/02

US-CL-PUBLISHED: 424/200.1; 424/257.1, 424/258.1, 424/261.1
US-CL-CURRENT: 424/200.1; 424/257.1, 424/258.1, 424/261.1

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention is directed towards compositions containing pathogenic bacteria (e.g. Haemophilus, E. Coli, and/or Salmonella) having non-reverting genetic mutations which alter activity of DNA adenine methylase (Dam) and methods using these compositions to elicit an immune response to produce highly specific antibodies. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.

CROSS-REFERENCE

[0001] This patent application is a continuation-in-part of U.S. patent application Ser. No. 09/612,116 filed Jul. 7, 2000 which is a continuation-in-part of U.S. patent application Ser. No. 09/495,614, filed Feb. 1, 2000, which claims the priority benefit of U.S. patent application Ser. Nos. 09/241,951, filed Feb. 2, 1999, converted to U.S. Provisional Ser. Nos. 60/183,043, and 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. 60/198,250, all of which are incorporated by reference in their entirety and to which applications is claimed priority.

Previous Doc Next Doc Go to Doc#

L3: Entry 28 of 54 File: USPT Oct 9, 2001

DOCUMENT-IDENTIFIER: US 6300084 B1
TITLE: Anti-mitotic agent screening process

CLAIMS:

1. A method for screening potential anti-mitotic agents comprising:

a) providing one or more purified proteins that are required for yeast mitotic spindle formation, wherein the one or more proteins are selected from the group consisting of a protein encoded by the yeast gene YGR113w (Dam I), and proteins provided in a complex of the Duo 1 protein encoded by the yeast gene YGL061 c and the Dam I protein encoded by the yeast gene YGR113w,

b) combining in vitro said one or more proteins with microtubules, and a potential anti-mitotic agent;

c) incubating said one or more proteins, said microtubules, and said anti-mitotic agent;

d) assaying the microtubules for binding of said one or more proteins; and

e) identifying an anti-mitotic agent, wherein said anti-mitotic agent inhibits binding of said one or more proteins to said microtubules.

2. The method according to claim 1, wherein said microtubules comprise bovine brain microtubules.

3. The method according to claim 1, wherein said microtubules comprise mammalian microtubules.

4. The method according to claim 1, wherein said assaying comprises pelleting said microtubules by ultracentrifugation followed by polyacrylamide gel electrophoresis of the pellets to assess the inhibition of binding of said one or more proteins to said microtubules.

5. The method according to claim 1, wherein said assaying comprises attaching a fluorescent probe to at least one of said one or more proteins and assessing the inhibition of binding of said one or more proteins to said microtubules by measuring the amount of said fluorescent probe on said microtubules.

6. The method according to claim 5, wherein measuring comprises Fluorescent Resonance Energy Transfer (FRET) or fluorescence anisotropy.

7. The method according to claim 1, wherein said one or more proteins required for mitotic spindle formation consists of the Dam1p protein encoded by the yeast gene YGR113w.

8. The method according to claim 1, wherein said one or more proteins required for mitotic spindle formation are provided in a complex of the Duo1 protein encoded by the yeast gene YGL161c and the Dam1p protein encoded by the yeast gene YGR113w.

9. The method according to claim 8, wherein the assay for binding is an assay for assessing the binding of said complex to said microtubules.

Previous Doc Next Doc Go to Doc#

L3: Entry 34 of 54 File: USPT Jun 6, 2000

US-PAT-NO: 6072102
DOCUMENT-IDENTIFIER: US 6072102 A

TITLE: Reversible nuclear genetic system for male sterility in transgenic plants

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cigan; Andrew M.	Des Moines	IA		
Albertsen; Marc C.	Des Moines	IA		

US-CL-CURRENT: 800/274; 536/24.1, 800/271, 800/275, 800/285, 800/288

CLAIMS:

What is claimed is:

1. A recombinant DNA molecule comprising:

(i) a lexA DNA binding site embedded in a tissue specific promoter which is operatively linked to a first DNA sequence encoding a gene product which when expressed in a plant inhibits or disrupts pollen formation or function, and

(ii) a second DNA sequence encoding a lexA repressor, which DNA sequence is operatively linked to an inducible promoter.

2. The recombinant DNA molecule of claim 1, wherein the tissue specific promoter is an anther-specific promoter.

3. The recombinant DNA molecule of claim 1, wherein the gene product is a cytotoxin.

4. The recombinant DNA molecule of claim 1, wherein the gene product is a diphtheria toxin A-chain.

5. The recombinant DNA molecule of claim 1, wherein the first DNA sequence is a cell cycle division mutant gene.

6. The recombinant DNA molecule of claim 5, wherein the cell cycle division mutant gene is selected from the group consisting of CC gene from maize, WT gene and P68.

7. The recombinant DNA molecule of claim 1, wherein the gene product is a methylase.

8. The recombinant DNA molecule of claim 7, wherein the methylase is a DAM methylase.

9. The recombinant DNA molecule of claim 1, wherein the inducible promoter is inducible by a chemical herbicidal safener.

10. The recombinant DNA molecule of claim 1, wherein the tissue specific promoter is an anther-specific promoter, the gene product is a DAM methylase, and the inducible promoter is inducible by a chemical herbicidal safener.

11. A plant cell comprising the recombinant DNA molecule of claim 1.

12. A plant comprising the recombinant DNA molecule of claim 1.

13. A method for producing reversible male sterility in a plant, comprising:

(a) providing a plant comprising a recombinant DNA molecule comprising

(i) a lexA DNA binding site embedded in a tissue specific promoter which is operatively linked to a first DNA sequence encoding a gene product which when expressed in a plant inhibits or disrupts pollen formation or function, and

(ii) a second DNA sequence encoding a lexa repressor, which DNA sequence is operatively linked to an inducible promoter; and

(b) exposing the plant to an inducer to reverse the male sterile effect of the recombinant DNA molecule.

14. The method of claim 13, wherein the tissue specific promoter is an anther-specific promoter.

15. The method of claim 13, wherein the gene product is a cytotoxin.

16. The method of claim 13, wherein the gene product is a methylase.

17. The method of claim 16, wherein the methylase is a DAM methylase.

18. The method of claim 13, wherein the inducer is an chemical herbicidal safener.

19. The method of claim 13, wherein the tissue specific promoter is an anther-specific promoter, the gene product is a DAM methylase, and the chemical inducer is a chemical inducer.

Previous Doc Next Doc Go to Doc#